Candel Therapeutics (Series C)
Funding Details
Awarder
Inbox
Date Award
April 2, 2019
Vertical
Immuno-oncology
Funding URL
View Funding Page
Funding Amount
$22,500,000
Company Info
Founders
Estuardo Aguilar-Cordova
Market
Solid tumors
Location
Auburndale, MA, USA
Coinvestors
H7 Holdings, Level One Partners, Northpond Ventures, Sands Capital
Company Description

Advantagene, Inc. d.b.a. Candel Therapeutics is developing proprietary immuno-oncology platforms, including its Gene Mediated Cytotoxic Immunotherapy (GMCI) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors.

Links
Website
Back to HomeBack to Immuno-oncology DealsView Funding Announcement